Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Werner Christian Neubauer; Monika Engelhardt; Armin König; Stefanie Hieke; Manfred Jung; Hartmut Bertz; Klaus Kümmerer

doi:10.1128/AAC.00150-10

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Werner Christian Neubauer
, Monika Engelhardt
, Armin König
, Stefanie Hieke
, Manfred Jung
, Hartmut Bertz
, Klaus Kümmerer

Universitätsklinikum Freiburg

Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

29 Zitate (Scopus)

Abstract

Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Originalsprache	Englisch
Zeitschrift	Antimicrobial Agents and Chemotherapy
Jahrgang	54
Ausgabenummer	9
Seiten (von - bis)	4029-4032
Seitenumfang	4
ISSN	0066-4804
DOIs	https://doi.org/10.1128/AAC.00150-10
Publikationsstatus	Erschienen - 09.2010
Extern publiziert	Ja

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Fachgebiete und Schlagwörter

Chemie

ASJC Scopus Sachgebiete

Pharmakologie
Infektionskrankheiten
Pharmakologie (medizinische)

Zugriff auf Dokument

10.1128/AAC.00150-10

Dieses zitieren

@article{ed6522367c874d37bc534e2f3584c839,

title = "Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method",

abstract = "Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright {\textcopyright} 2010, American Society for Microbiology. All Rights Reserved.",

keywords = "Chemistry, Adult, Aged, Antifungal Agents, Chromatography, High Pressure Liquid, Female, Hematologic Neoplasms, Humans, Male, Middle Aged, Mycoses, Prospective Studies, Triazoles",

author = "Neubauer, \{Werner Christian\} and Monika Engelhardt and Armin K{\"o}nig and Stefanie Hieke and Manfred Jung and Hartmut Bertz and Klaus K{\"u}mmerer",

year = "2010",

month = sep,

doi = "10.1128/AAC.00150-10",

language = "English",

volume = "54",

pages = "4029--4032",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society For Microbiology",

number = "9",

}

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. / Neubauer, Werner Christian; Engelhardt, Monika; König, Armin et al.
in: Antimicrobial Agents and Chemotherapy, Jahrgang 54, Nr. 9, 09.2010, S. 4029-4032.

Publikation: Beiträge in Zeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

AU - Neubauer, Werner Christian

AU - Engelhardt, Monika

AU - König, Armin

AU - Hieke, Stefanie

AU - Jung, Manfred

AU - Bertz, Hartmut

AU - Kümmerer, Klaus

PY - 2010/9

Y1 - 2010/9

N2 - Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

AB - Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

KW - Chemistry

KW - Adult

KW - Aged

KW - Antifungal Agents

KW - Chromatography, High Pressure Liquid

KW - Female

KW - Hematologic Neoplasms

KW - Humans

KW - Male

KW - Middle Aged

KW - Mycoses

KW - Prospective Studies

KW - Triazoles

UR - https://www.scopus.com/pages/publications/77956122820

UR - https://www.mendeley.com/catalogue/ddfbf767-8284-3f5d-99ee-36156fbeae27/

U2 - 10.1128/AAC.00150-10

DO - 10.1128/AAC.00150-10

M3 - Journal articles

C2 - 20547790

SN - 0066-4804

VL - 54

SP - 4029

EP - 4032

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 9

ER -

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Abstract

UN SDGs

Fachgebiete und Schlagwörter

ASJC Scopus Sachgebiete

Zugriff auf Dokument

Fingerprint

Dieses zitieren